Literature DB >> 17624663

High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma.

Norihiko Akamatsu1, Yasuaki Yamada, Hiroo Hasegawa, Koki Makabe, Ryutaro Asano, Izumi Kumagai, Ken Murata, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kazuto Tsuruda, Kazuyuki Sugahara, Sunao Atogami, Katsunori Yanagihara, Shimeru Kamihira.   

Abstract

We surveyed IL-21 receptor (IL-21R) in leukemia and lymphoma and found that follicular lymphoma cells showed exceptionally high IL-21R expression. Notably, IL-21 showed divergent effects depending on the cell origin: growth stimulation in Burkitt lymphoma cell lines and adult T cell leukemia/lymphoma cell lines but induction of apoptosis in B lymphoma cell lines with t(14;18)(q32;q21), a marker karyotype of follicular lymphoma. IL-21 activated caspase-8 and -3 and reduced mitochondrial membrane potential. More importantly, IL-21 decreased Bcl-2 expression but increased Bax expression. These results support a new therapeutic approach using the IL-21/IL-21R system in follicular lymphoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624663     DOI: 10.1016/j.canlet.2007.06.001

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

Review 2.  Interleukin-21: a double-edged sword with therapeutic potential.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

Review 3.  The follicular lymphoma microenvironment: From tumor cell to host immunity.

Authors:  Antonio Martinez; Joaquim Carreras; Elias Campo
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

4.  A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.

Authors:  John M Timmerman; John C Byrd; David J Andorsky; Reiko E Yamada; Janet Kramer; Natarajan Muthusamy; Naomi Hunder; John M Pagel
Journal:  Clin Cancer Res       Date:  2012-08-14       Impact factor: 12.531

5.  IL-21 receptor signaling is essential for control of hepatocellular carcinoma growth and immunological memory for tumor challenge.

Authors:  Xinchun Zheng; Yang Zhou; Xuan Yi; Chengcong Chen; Chunhua Wen; Guofu Ye; Xiaoyi Li; Libo Tang; Xiaoyong Zhang; Fuqiang Yang; Guangze Liu; Yongyin Li; Jinlin Hou
Journal:  Oncoimmunology       Date:  2018-09-26       Impact factor: 8.110

6.  Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Authors:  Shruti Bhatt; Julie Matthews; Salma Parvin; Kristopher A Sarosiek; Dekuang Zhao; Xiaoyu Jiang; Elif Isik; Anthony Letai; Izidore S Lossos
Journal:  Blood       Date:  2015-07-20       Impact factor: 22.113

7.  Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.

Authors:  Kristopher A Sarosiek; Raquel Malumbres; Hovav Nechushtan; Andrew J Gentles; Eli Avisar; Izidore S Lossos
Journal:  Blood       Date:  2009-11-20       Impact factor: 22.113

8.  IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.

Authors:  Jennifer Dien Bard; Pascal Gelebart; Mona Anand; Zoulika Zak; Samar A Hegazy; Hesham M Amin; Raymond Lai
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

9.  IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.

Authors:  Katherine R Calvo; Bhavana Dabir; Alexandra Kovach; Christopher Devor; Russell Bandle; Amelia Bond; Joanna H Shih; Elaine S Jaffe
Journal:  Blood       Date:  2008-08-05       Impact factor: 22.113

10.  Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.

Authors:  Marieta Caganova; Chiara Carrisi; Gabriele Varano; Federica Mainoldi; Federica Zanardi; Pierre-Luc Germain; Laura George; Federica Alberghini; Luca Ferrarini; Asoke K Talukder; Maurilio Ponzoni; Giuseppe Testa; Takuya Nojima; Claudio Doglioni; Daisuke Kitamura; Kai-M Toellner; I-hsin Su; Stefano Casola
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.